DeepSight Unveils Tech to Upgrade Any Ultrasound for Precision Guidance

TORONTO, ON – April 08, 2026 – DeepSight Technology, a firm at the forefront of sensor-enabled medical imaging, today announced a significant expansion of its technology portfolio at the Society of Interventional Radiology (SIR) 2026 Annual Meeting. The company is showcasing its comprehensive NeedleVue™ platform, a suite of solutions designed to bring sub-millimeter accuracy to ultrasound-guided procedures. The centerpiece of the announcement is the debut of the NeedleVue™ Mini, a compact, system-agnostic device intended to bring advanced guidance capabilities to virtually any existing ultrasound machine.

This move marks a major strategic shift for the Santa Clara-based company, moving from a single-product focus to a multi-pronged platform strategy. The goal is to make high-precision instrument tracking more accessible across a wide spectrum of clinical environments, from major medical centers to smaller community clinics. The NeedleVue platform now comprises three distinct offerings: a standalone system, an embeddable module for OEM partners, and the new universal bolt-on solution.

"This is a pivotal moment for DeepSight," said Nader Sadrzadeh, CEO of DeepSight Technology, in the company's official announcement. "We are moving beyond developing a single product to a platform strategy that meets clinicians and partners where they are—whether through a dedicated system, seamless OEM integration, or a simple add-on to existing ultrasound equipment. Our mission is to deliver precision, clarity, and confidence in every procedure and for every patient."

The 'Any Ultrasound' Revolution

The introduction of the NeedleVue™ Mini represents a potential turning point in the accessibility of advanced interventional tools. Designed as a "bolt-on" solution, the Mini can be connected to the vast majority of ultrasound systems already in use in hospitals and clinics worldwide. This approach directly addresses one of the most significant barriers to adopting new medical technology: the high capital cost of replacing functional, but less advanced, equipment.

Globally, more than 200 million needle-based procedures are performed annually, a number that is steadily increasing. While ultrasound is a common, radiation-free imaging tool for guiding these interventions, clinicians often face challenges with poor needle visibility and unreliable instrument tracking, especially in deep tissue or complex patient anatomy. DeepSight's technology aims to solve this "visualization gap."

The market for a system-agnostic solution is substantial. Cart-based ultrasound units, the primary target for the NeedleVue Mini, are projected to account for over 65% of the global ultrasound market, which itself is forecasted to grow from USD 10.80 billion in 2025 to over USD 20 billion by 2034. By allowing healthcare providers to upgrade their existing infrastructure, the NeedleVue Mini could dramatically expand the reach of precision guidance, improving procedural outcomes and patient safety without requiring a complete system overhaul.

A Strategic Pivot to a Platform Ecosystem

Beyond the groundbreaking Mini, DeepSight's showcase at SIR 2026 highlights a deliberate and sophisticated business strategy. The comprehensive NeedleVue platform is designed as an ecosystem to penetrate the medical device market from multiple angles.

The first component is the NeedleVue™ LiteCart, an FDA-cleared, dedicated interventional ultrasound system that comes with the company's guidance technology fully integrated. This standalone unit is aimed at institutions looking to acquire a complete, state-of-the-art system designed for streamlined workflow and real-time instrument tip visualization.

The second prong is the NeedleVue™ Embedded (NVE), an OEM-integrated solution. This allows other medical device manufacturers to incorporate DeepSight's guidance platform directly and seamlessly into their own technology. This B2B approach enables partners to add sophisticated imaging and tracking to their instruments—such as ablation probes, biopsy tools, or catheters—and is key to DeepSight's plan to scale its technology across a vast array of medical specialties and applications.

Together, these three solutions—the standalone LiteCart, the embeddable NVE, and the universal Mini—create a flexible and scalable commercialization model. This strategy allows DeepSight to cater to the full spectrum of customer needs, from large hospitals investing in new fleets to smaller practices seeking cost-effective upgrades and OEM partners innovating in the minimally invasive device space.

Under the Hood: The Sensor Redefining Visualization

At the heart of the entire NeedleVue platform is a proprietary acousto-optic sensor that is approximately 50 microns in size—smaller than the diameter of a human hair. This microscopic sensor is embedded at the tip of an interventional instrument, such as a needle. By passively detecting incoming ultrasound signals, the system can calculate the precise location of the instrument's tip in real time with sub-millimeter accuracy.

This core technology, protected by a portfolio of over 120 patents, offers several key advantages over conventional ultrasound visualization. The sensor is non-electrical and inert, making it impervious to magnetic fields or the temperature extremes found in ablation procedures. It provides omnidirectional tracking, meaning it can accurately locate the instrument tip across wide angles and depths, whether it is in or out of the primary imaging plane. This overcomes a common frustration where the needle shaft is visible but the critical tip is not.

Clinicians who have seen demonstrations have reportedly expressed significant enthusiasm for the technology's ability to provide a clear, unambiguous view of the instrument tip even in challenging conditions, such as within dense tissue or vision-obscuring ablation clouds. This enhanced clarity and control promises to improve the safety and efficacy of a wide range of procedures, potentially reducing complication rates and improving biopsy success on the first attempt.

Navigating the Path to Market

While the technology's potential is significant, its rollout will be methodical. DeepSight has already achieved a major milestone with U.S. Food and Drug Administration (FDA) 510(k) clearance for its NeedleVue LC1 Ultrasound System, the standalone cart-based platform. This clearance, granted in August 2025, covers a range of applications including abdominal, vascular, and musculoskeletal imaging.

However, it is critical to note that the newly debuted NeedleVue Mini and the NeedleVue Embedded solutions are investigational devices. According to the company, they have not yet been reviewed or authorized for marketing by any regulatory authority, and a timeline for submission and approval in key markets like the U.S. and Europe has not been made public. The initial focus for the platform's applications is on ultrasound-guided abdominal biopsies, with plans to expand into the rapidly growing fields of interventional oncology, vascular access, and other minimally invasive procedures.

For now, the showcase at SIR 2026 serves as a major introduction to the clinical community. The live demonstrations and expert-led discussions at DeepSight's booth are intended to build excitement and gather feedback from the interventional radiologists who stand to benefit most from this leap in visualization technology.